AAML1831:CPX-351对比标准诱导治疗初诊儿童AML的III期试验
中期分析显示CPX-351组无事件生存劣于DA组,随机分配提前终止,低危患者无病生存更低且累积复发率更高。
要点
- CPX-351诱导在儿童及年轻成人AML中无事件生存劣于标准DA方案。
- 低危患者接受CPX-351后无病生存显著降低且复发率更高。
- 高危患者两方案无病生存相当。
核心结论
- 在AAML1831试验中,CPX-351诱导劣于DA诱导,无事件生存差异主要由低危患者事件驱动。
主要发现
- 中期分析因CPX-351组无事件生存劣于DA组而跨越无效性监测规则,随机分配停止。
- 从研究入组起2年无事件生存率DA组为62.2%,CPX-351组为51.2%(P = .011)。
- 高危患者两方案无病生存相当。
- 低危患者CPX-351组对比DA组:从诱导1结束起2年无病生存率57.5% vs 73.8%(P = .001),2年累积复发率39.9% vs 23.6%(P = .001)。
临床怎么用
- 在儿童及年轻成人初诊AML中,CPX-351诱导不应替代标准DA诱导方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Children's Oncology Group phase III clinical trial AAML1831 (ClinicalTrials.gov identifier: NCT04293562) evaluated liposomal daunorubicin and cytarabine (CPX-351) versus standard daunorubicin/cytarabine (DA) induction therapy in children and young adults with newly diagnosed AML. We hypothesized that CPX-351 given during induction 1 and 2 would improve outcomes compared with DA. PATIENTS AND METHODS: Patients (21 years and younger) were randomly assigned to two cycles of DA induction (arm A = DA) or CPX-351 (arm B = CPX-351). All patients also received gemtuzumab ozogamicin in induction 1. Postinduction chemotherapy was according to risk assignment made at the end of induction 1 (EOI1). Those with high-risk (HR) AML received consolidation with allogeneic hematopoietic stem-cell transplantation (HSCT), whereas low-risk (LR) patients received chemotherapy alone. Protocol-specified interim analysis monitored efficacy and futility of CPX-351 induction with respect to the primary end point, event-free survival (EFS) from study entry. Disease-free survival (DFS) was calculated to determine the impact of EOI1 risk assignment. RESULTS: Seven hundred twenty-one eligible patients with FLT3 wild-type AML were randomly assigned to DA (n = 358) or CPX-351 (n = 363). Interim analysis determined that the futility monitoring rule was crossed because of inferior EFS in the CPX-351 arm and the random assignment was stopped. The two-year EFS from study entry was 62.2% for DA versus 51.2% for CPX-351 (P = .011). DFS for patients with HR AML was comparable for both arms. However, DFS was significantly lower and cumulative incidence of relapse (CIR) was higher for LR patients assigned to CPX-351 versus DA (2-year DFS from EOI1: DA: 73.8% v CPX-351 57.5% [P = .001]; 2-year CIR Arm DA: 23.6% v CPX-351: 39.9% [P = .001]). CONCLUSION: CPX-351 was inferior to DA induction in the AAML1831 trial with differential EFS largely driven by events in LR patients.
引用
- Pollard JA, Alonzo TA, Gerbing RB, et al. AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group. J Clin Oncol. 2026. PMID: 42497367. doi:10.1200/JCO-25-02979
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。